Retatrutide: The Triple Agonist GLP-1 Guide (2026)

Retatrutide (LY3437943) is a next-generation weight loss medication unlike anything before it. While semaglutide targets one receptor and tirzepatide targets two, retatrutide simultaneously activates three: GLP-1, GIP, and glucagon. This triple-receptor approach has produced the highest weight loss numbers ever recorded in a Phase 3 obesity trial — 28.7% average body weight reduction at 68 weeks.

If you've been following the GLP-1 space, you already know how dramatic the progression has been. Semaglutide (Ozempic/Wegovy) changed medicine with ~15% weight loss. Tirzepatide (Mounjaro/Zepbound) pushed that to ~22.5%. Retatrutide is now showing results that sound almost too good to be true. This guide covers everything you need to know: the science, the clinical data, the side effects, and where things stand in 2026.

What Is Retatrutide?

Retatrutide is an investigational once-weekly subcutaneous injection developed by Eli Lilly and Company. It is a synthetic peptide engineered to be a triple agonist — meaning it simultaneously activates three distinct hormone receptors:

• GLP-1 (glucagon-like peptide-1) receptor — slows gastric emptying, increases satiety, reduces appetite
• GIP (glucose-dependent insulinotropic polypeptide) receptor — enhances insulin secretion, improves fat metabolism
• Glucagon (GCG) receptor — increases energy expenditure, stimulates fat breakdown, reduces liver fat

The glucagon component is what sets retatrutide apart from all previous GLP-1 medications. Glucagon normally raises blood sugar — but when its receptor is activated alongside GLP-1 and GIP receptors, the hyperglycemic effects are balanced, leaving only the metabolic benefits: increased calorie burn and accelerated fat breakdown.

How Retatrutide Works: The Science of Triple Agonism

GLP-1 Receptor Agonism

GLP-1 agonism is the foundation of modern weight loss pharmacotherapy. When activated, GLP-1 receptors slow gastric emptying, signal the hypothalamus to reduce hunger, stimulate glucose-dependent insulin release, and suppress pancreatic glucagon secretion.

GIP Receptor Agonism

GIP amplifies GLP-1 effects, enhances insulin secretion synergistically, improves peripheral insulin sensitivity, and may reduce the severity of GLP-1-associated nausea through complementary pathways.

Glucagon Receptor Agonism — The Game Changer

This is where retatrutide diverges from tirzepatide. Glucagon receptor activation adds:

• Increased energy expenditure — the body burns more calories at rest
• Enhanced lipolysis — accelerated breakdown of stored body fat
• Reduced lipogenesis — less new fat is synthesized
• Improved liver fat clearance — meaningful benefit for metabolic fatty liver disease (MASLD)

Retatrutide is most potent at the GIP receptor (EC50: 0.064 nM), less potent at GLP-1 (EC50: 0.78 nM), and least potent at glucagon (EC50: 5.79 nM). This calibrated potency ratio is intentional — enough glucagon activity to drive energy expenditure without pushing blood sugar dangerously high.

Clinical Trial Results: The TRIUMPH Program

Eli Lilly's Phase 3 program is called TRIUMPH (TRIple hormone receptor agonist for Underpinning Metabolic PHenomena). Eight trials evaluate retatrutide across obesity, type 2 diabetes, osteoarthritis, sleep apnea, MASLD, and cardiovascular outcomes.

Phase 2 Results (NEJM, 2023)

The Phase 2 trial published in the New England Journal of Medicine was the first major signal. At 12 mg, participants lost an average of 24.2% of body weight at 48 weeks — compared to roughly 15% for semaglutide and ~20% for tirzepatide at comparable timepoints. The results set expectations for Phase 3 extraordinarily high.

TRIUMPH-4: Obesity + Osteoarthritis (December 2025)

The first Phase 3 readout came in December 2025. In people with obesity and knee osteoarthritis, at 68 weeks:

• 12 mg dose: Average weight loss of 23.7% (~71 lbs / 32 kg)
• 9 mg dose: Average weight loss of 20.0%
• Placebo: 4.6% weight loss

Knee pain (WOMAC subscale) improved by 62–67% versus 35% with placebo — remarkable joint pain relief as a secondary benefit.

Primary Obesity Trial: 28.7% Average Weight Loss

The headline result: at 12 mg over 68 weeks, participants lost an average of 28.7% of body weight. This is the highest weight loss ever recorded in a Phase 3 obesity trial for any medication. For context, bariatric surgery typically produces 25–35% weight loss.

At the 9 mg dose, average weight loss was 26.4%.

TRANSCEND-T2D-1: Type 2 Diabetes (March 2026)

In people with type 2 diabetes, retatrutide reduced A1C by up to 2.0 percentage points while producing 16.8% average weight loss — best-in-class results for a diabetes medication.

Retatrutide vs. Semaglutide vs. Tirzepatide

Each receptor layer adds clinically meaningful weight loss. Retatrutide exceeds tirzepatide by more than 6 percentage points — a substantial gap at population scale, and likely a meaningful difference in practice for patients who need maximum results.

Side Effects and Tolerability

Side effects are largely consistent with the GLP-1 drug class. At the 12 mg dose in Phase 3:

• Nausea: 43.2% (vs. 10.7% placebo)
• Diarrhea: 33.1% (vs. 13.4% placebo)
• Constipation: 25.0% (vs. 8.7% placebo)
• Vomiting: 20.9%
• Dysesthesia (unusual skin sensations): ~20.9% — less common with other GLP-1 drugs, possibly related to glucagon receptor activity

Discontinuation Rates: An Important Caveat

A notable tolerability concern: 18.2% of participants on 12 mg discontinued due to adverse events, compared to 4% on placebo. Some discontinuations were because participants lost weight faster than anticipated. The 9 mg dose saw 12.2% discontinuation.

These rates are higher than semaglutide or tirzepatide, suggesting that glucagon-mediated effects may make retatrutide harder to tolerate for some patients. Careful dose titration and patient selection will matter.

Dosing in Clinical Trials

Important: Retatrutide is not FDA-approved. This information reflects clinical trial protocols only — not prescription dosing guidance.

In the TRIUMPH trials, retatrutide was given as a once-weekly subcutaneous injection with structured escalation:

• Starting dose: 2 mg once weekly
• Escalation: Progressive increases every 4 weeks
• Maintenance doses studied: 4 mg, 9 mg, and 12 mg

Slow dose escalation — standard across the GLP-1 class — is designed to allow GI adaptation and minimize early-treatment side effects.

What Conditions Is Retatrutide Being Studied For?

TRIUMPH includes eight Phase 3 trials evaluating retatrutide in:

• Obesity (primary indication)
• Type 2 diabetes
• Knee osteoarthritis
• Obstructive sleep apnea
• Chronic low back pain
• Cardiovascular and renal outcomes
• Metabolic dysfunction-associated steatotic liver disease (MASLD)

This breadth underscores how a drug producing 25–30% weight loss could reshape the treatment of a wide range of obesity-related diseases.

FDA Approval Timeline

As of April 2026, no NDA has been filed. Eli Lilly's projected timeline:

• NDA submission: Q4 2026
• FDA review: ~10–12 months after submission
• Potential approval: Late 2027 to mid-2028

Commercially available retatrutide is at minimum 18 months away under the most optimistic projections.

Can You Get Compounded Retatrutide?

No — and this matters. Unlike semaglutide and tirzepatide, which entered compounding pharmacy channels through FDA shortage designations, retatrutide has never been approved and has never appeared on the FDA shortage list.

The FDA has explicitly stated that retatrutide cannot be used in compounding under federal law. Any pharmacy selling "compounded retatrutide" is operating illegally. Even after FDA approval, compounding would only be lawful if retatrutide appeared on the shortage list — which is unlikely given Eli Lilly's scale.

Sites selling retatrutide peptides are selling unregulated research chemicals with unknown purity, potency, and safety profiles. The risks are real and unquantified.

Who Might Benefit Most?

Based on trial data, retatrutide will likely appeal most to:

• People who haven't achieved sufficient results with semaglutide or tirzepatide
• Those with type 2 diabetes needing both maximum weight loss and glycemic control
• People with obesity-related joint pain or osteoarthritis
• Those with fatty liver disease (MASLD)
• Patients pursuing maximum pre-surgical weight reduction

The Bottom Line

Retatrutide is the most impressive weight loss drug yet studied in large-scale clinical trials. Its 28.7% average weight loss in Phase 3 is genuinely unprecedented — edging into territory previously associated only with bariatric surgery.

The tradeoffs are real: higher dropout rates and a tolerability profile that won't work for everyone. But for the large population of people living with severe obesity and its consequences — type 2 diabetes, joint destruction, sleep apnea, fatty liver — a once-weekly injection producing surgical-level weight loss would be transformative.

It isn't available yet. NDA submission is expected in Q4 2026, with approval possibly arriving in late 2027. Until then, semaglutide and tirzepatide remain the most effective approved options. But retatrutide is coming — and the data suggests it will change the standard of care.